317 related articles for article (PubMed ID: 7060020)
1. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.
Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020
[TBL] [Abstract][Full Text] [Related]
2. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
3. Antitumor spectrum of a new anthracycline, (2"R)-4'-O-tetrahydropyranyladriamycin, and effect on the cellular immune response in mice.
Hisamatsu T; Suzuki K; Sakakibara S; Komuro K; Nagasawa M; Takeuchi T; Umezawa H
Jpn J Cancer Res; 1985 Oct; 76(10):1008-20. PubMed ID: 3935619
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
5. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
Dawson KM
Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
[TBL] [Abstract][Full Text] [Related]
6. Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.
Wallace RE; Murdock KC; Angier RB; Durr FE
Cancer Res; 1979 May; 39(5):1570-4. PubMed ID: 427798
[TBL] [Abstract][Full Text] [Related]
7. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
8. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
9. Treatment of mouse tumors with 7-con-O-methylnogarol and other analogs of the anthracycline antibiotic, nogalamycin.
Neil GL; Kuentzel SL; McGovren JP
Cancer Treat Rep; 1979; 63(11-12):1971-8. PubMed ID: 526931
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines.
Nakanishi O; Baba M; Saito A; Yamashita T; Sato W; Abe H; Fukazawa N; Suzuki T; Sato S; Naito M; Tsuruo T
Oncol Res; 1997; 9(2):61-9. PubMed ID: 9167187
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
[TBL] [Abstract][Full Text] [Related]
12. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
Sugimoto Y; Matsuo K; Takeda S; Yamada Y; Tsukagoshi S
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003
[TBL] [Abstract][Full Text] [Related]
13. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
14. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of antitumor activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine in murine tumors.
Furusawa S; Mian AM
Cancer Treat Rep; 1987 May; 71(5):441-6. PubMed ID: 3567967
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of an alpha-picoline derivative, penclomedine (NSC 338720), on human and murine tumors.
Plowman J; Harrison SD; Dykes DJ; Paull KD; Narayanan VL; Tobol HK; Martin J; Griswold DP
Cancer Res; 1989 Apr; 49(8):1909-15. PubMed ID: 2702634
[TBL] [Abstract][Full Text] [Related]
18. In vitro antitumor activity of 4'-O-tetrahydropyranyladriamycin on human gastric cancer cells.
Yamaue H; Tanimura H; Noguchi K; Shono Y; Iwahashi M; Hotta T; Tani M; Tsunoda T; Nishimoto N; Terasawa H; Nakamori M
Anticancer Res; 1996; 16(1):243-6. PubMed ID: 8615614
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma.
Lippman MM; Laster WR; Abbott BJ; Venditti J; Baratta M
Cancer Res; 1975 Apr; 35(4):939-45. PubMed ID: 1116151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]